First human test for Next-Generation cholera vaccine begins
NCT ID NCT07270796
Summary
This early-stage study aims to test the safety and immune response of a new oral cholera vaccine called DuoChol. Sixty healthy adults in Sweden will receive either the new vaccine or an existing vaccine (Dukoral®) in two doses, two weeks apart. Researchers will monitor participants for side effects and measure how well their immune systems respond to the vaccine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLERA VACCINATION REACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Studieenheten Akademiskt Specialistcentrum
Stockholm, Sweden
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.